Flag of the European Union EU Clinical Trials Register Help

Clinical trials for TAVR

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: TAVR. Displaying page 1 of 1.
    EudraCT Number: 2016-001777-33 Sponsor Protocol Number: EARTH-TAVR01 Start Date*: 2016-09-01
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: EVALUATION OF CEREBRAL THROMBOEMBOLISM AFTER TAVR
    Medical condition: Patients with severe aortic stenosis that require Transcatheter aortic valve replacement are at risk for stroke. This study is to evaluate the occurrence and extent of cerebral embolization (total...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10002916 Aortic valve replacement PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001975-30 Sponsor Protocol Number: BAY59-7939/17938 Start Date*: 2016-01-12
    Sponsor Name:Bayer AG
    Full Title: Global multicenter, open-label, randomized, event-driven, active-controlled study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc ...
    Medical condition: Patients with severe aortic stenosis that require Transcatheter aortic valve replacement are at risk of thrombus formation. Rivaroxaban (oral-anticoagulant) may reduce this risk, without increasing...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10002916 Aortic valve replacement PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) NO (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) SE (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000632-26 Sponsor Protocol Number: TMC-BIV-11-02 Start Date*: 2013-03-22
    Sponsor Name:The Medicines Company
    Full Title: Effect of Bivalirudin on Aortic Valve Intervention Outcomes 2/3
    Medical condition: Patients undergoing transcatheter aortic valve replacement (TAVR) procedures performed via the transfemoral approach.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10042613 - Surgical and medical procedures 10002916 Aortic valve replacement PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-004271-14 Sponsor Protocol Number: DAPAS Start Date*: 2021-12-06
    Sponsor Name:Aarhus University Hospital, department of Cardiology
    Full Title: Effect of Dapagliflozin on myocardial and renal function following aortic valve stenosis intervention
    Medical condition: Patients with aortic stenosis undergoing trans catheter aortic valve replacement.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10058186 Aortic valve stenosis and insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005710-19 Sponsor Protocol Number: M13-958 Start Date*: 2013-10-28
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High ...
    Medical condition: Acute Kidney Injury
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10069339 Acute kidney injury LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003361-19 Sponsor Protocol Number: H-19078792 Start Date*: 2020-09-07
    Sponsor Name:Rigshospitalet
    Full Title: Prospective study on the impact of different anti-thrombotic therapies on subclinical leaflet thickening and its temporal dynamics in transcatheter bioprosthetic aortic valves The Nordic Aortic Val...
    Medical condition: Patients who have undergone successful transcatheter bioprosthetic aortic valve implantation (TAVI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10077017 TAVI LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000757-49 Sponsor Protocol Number: QRK309 Start Date*: 2018-12-05
    Sponsor Name:Quark Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for A...
    Medical condition: QPI-1002 is being developed for prevention of acute kidney injury (AKI) in patients at risk for AKI following cardiac surgery and for reduction in the incidence and severity of delayed graft functi...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10069339 Acute kidney injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) BE (Completed) CZ (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003113-15 Sponsor Protocol Number: QRK209 Start Date*: 2016-08-02
    Sponsor Name:Quark Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury in Subjects at High Risk for AKI following Ca...
    Medical condition: QPI-1002 is being developed for prevention of acute kidney injury (AKI) in patients at risk for AKI following cardiac surgery and for reduction in the incidence and severity of delayed graft functi...
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038359 - Renal and urinary disorders 10069339 Acute kidney injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 03:01:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA